IMVT

In December 2025, Immunovant announced the pricing of a $550 million common stock financing, expected to fund operations through a potential commercial launch of IMVT-1402 in Graves' disease, contributing to a stock price increase. In February 2026, the company reported financial results for the third quarter ended December 31, 2025, with the stock seeing a significant increase of +12.43% following the announcement, which included the full enrollment of the IMVT-1402 trial in D2T RA. In March 2026, Immunovant's shares surged 17% over three months, reflecting improving investor confidence. In April 2026, Immunovant announced Phase 3 study results for batoclimab in Thyroid Eye Disease (TED), which failed their primary endpoint, though safety remained consistent; despite this, Immunovant shares hit a new 52-week high, and insider selling was reported.